Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Approval Alert | Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20 NSCLC
3
Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC
4
How AI and Health Networks Are Democratizing Clinical Trial Access
5